TAI · —

Adimmune Corporation (4142.TW) Stock

$17.80 +0.00% TAI: 4142.TW —

—

Valuation

MetricValue
Price$17.80
Market Cap$8.09B
P/E Ratio160.00
P/B Ratio1.75
P/S Ratio5.91
EPS (TTM)$-0.34
52-Week High$22.50
52-Week Low$16.40
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-4.40%
ROA-1.99%
ROCE—
Gross Margin23.10%
Operating Margin-258.72%
Net Margin-10.48%
Debt/Equity0.64
Current Ratio4.47

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-110.56
FCF Yield—
Quick Ratio2.77
Interest Coverage—
Return 1Y-8.72%
Return 3Y-44.11%
Return 5Y-59.02%

Ownership

Insiders Held9.98%
Institutions Held14.65%
Institutions Float Held16.27%

About Adimmune Corporation

—

Adimmune Corporation is led by CEO Chi-Hsien Chan, employs 564 people, headquartered in Taichung, TW, publicly traded since 2012.

Adimmune Corporation (4142.TW) stock trades at $17.80 with a market capitalization of $8.09B. The stock is valued at a price-to-earnings (P/E) ratio of 160.00, price-to-book of 1.75, price-to-sales of 5.91. Over the past 52 weeks the stock has ranged between $16.40 and $22.50, and currently trades 20.9% below its 52-week high.

On profitability, Adimmune Corporation generates a return on equity (ROE) of -4.40% (negative, reflecting a net loss), an operating margin of -258.72%, a net profit margin of -10.48%.

Official website: www.adimmune.com.tw

Adimmune Corporation (4142.TW) — frequently asked questions

What is Adimmune Corporation (4142.TW) stock price today?

Adimmune Corporation (4142.TW) is currently trading at $17.80, up 0% today.

What is 4142.TW P/E ratio?

Adimmune Corporation's P/E ratio is 160.00. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.

What is 4142.TW return on equity (ROE)?

Adimmune Corporation's return on equity (ROE) is -4.40%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Adimmune Corporation's market cap?

Adimmune Corporation has a market capitalization of $8.09B.

Does 4142.TW pay a dividend?

Adimmune Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does 4142.TW carry?

Adimmune Corporation has a debt-to-equity ratio of 0.64. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is 4142.TW's profit margin?

Adimmune Corporation reports a net profit margin of -10.48% — the share of revenue left after every cost, including tax and interest.

What sector is 4142.TW in?

Adimmune Corporation is classified under —, in the — industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is 4142.TW listed on?

Adimmune Corporation trades on TAI under the ticker 4142.TW.

What is 4142.TW's 52-week range?

Over the last year Adimmune Corporation has traded between $16.40 and $22.50.

Related — Stocks

USDE StablecoinX Inc. $1.00 -0.01% APMD Apnimed, Inc. $18.99 +2.48% GLAS Glass House Brands Inc. Subordinate Voting Shares $2.14 -6.14% GIXI Gix Internet Ltd. $4.23 +4.44%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens 4142.TW currently matches

On the figures above, Adimmune Corporation passes the filters for 6 of our ready-made screens, among them High PE Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High PE StocksStocks Under $100Stocks Under $50Mid Cap StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.